Reagent access traceability management method suitable for intelligent reagent cabinet

Abstract

The invention relates to the technical field of reagent access traceability management, in particular to a reagent access traceability management method suitable for an intelligent reagent cabinet. The method comprises the following steps: firstly, acquiring the taking amount and taking duration of each reagent in each access process, and acquiring a taking interval sequence of each reagent; analyzing and acquiring a preliminary abnormal coefficient of each access process of each reagent so as to acquire all abnormal access processes and all normal access processes; the abnormal taking coefficient of each reagent is further obtained, the state abnormal index of each reagent is obtained in combination with the taking amount of each reagent in the storing and taking process, and therefore the abnormal reagents are screened out and subjected to traceability management. According to the invention, by analyzing the access change condition of each reagent in different access processes, the possibility of abnormal access and quality state change of the reagent is evaluated, so that the abnormal reagent can be accurately screened out for accurate traceability management.

Description

Technical Field

[0001] The present invention relates to the technical field of reagent storage and access traceability management, and in particular to a reagent storage and access traceability management method applicable to an intelligent reagent cabinet. Background Art

[0002] The intelligent reagent cabinet is a laboratory management device for storing various chemical reagents. It is widely used in biomedicine, environmental science, food science and other fields. It integrates information technologies such as Radio Frequency Identification (RFID) to authenticate personnel and control permissions, and track and record the storage environment and access information of reagents, so that the laboratory can trace the access of reagents, thereby improving the efficiency, safety and transparency of reagent management.

[0003] In the process of reagent management, the smart reagent cabinet can provide early warning and traceability management for abnormal situations such as chaotic storage of reagents and long-term non-return of reagents. However, it fails to conduct effective analysis and traceability for changes in the status of reagents. For example, if the status of the reagent changes due to improper operation during the use process, the smart reagent cabinet cannot determine the status of the reagent and directly records the stored information, making it impossible to discover or handle abnormal reagents in time, thereby affecting the management effect of the reagents. Summary of the invention

[0004] In order to solve the technical problem that the prior art has poor reagent storage and access management effect, the purpose of the present invention is to provide a reagent storage and access traceability management method suitable for an intelligent reagent cabinet, and the technical solution adopted is as follows: Obtain the amount and duration of each reagent in the intelligent reagent cabinet during each access process during the traceability management period, and obtain the access interval sequence of each reagent during the traceability management period; According to the amount of each reagent taken and the duration of the use in each access process, obtain the preliminary abnormal coefficient of each access process of each reagent; according to the preliminary abnormal coefficient, obtain all abnormal access processes and all normal access processes of each reagent; during the traceability management period of each reagent, according to the change of the access interval sequence and the preliminary abnormal coefficient of all the abnormal access processes, obtain the abnormal access coefficient of each reagent; According to the amount of each reagent taken during all the abnormal access processes, and the amount of each reagent taken during all the normal access processes, combined with the corresponding abnormal access coefficient, the state abnormality index of each reagent is obtained; according to the state abnormality index, abnormal reagents are screened out from all reagents, and access traceability management is performed on the abnormal reagents.

[0005] Furthermore, the method for obtaining the preliminary anomaly coefficient includes: Under each reagent, according to the deviation of the amount taken in each access process relative to the amounts taken in other access processes, and the deviation of the access time in each access process relative to the access time in other access processes, obtaining the access characteristic deviation parameter; In each access process of each reagent, the product of the access amount and the access time is used as an access characteristic parameter; The feature parameters and the feature deviation parameters are integrated to obtain a preliminary anomaly coefficient.

[0006] Furthermore, the method for obtaining the characteristic deviation parameter includes: In each access process of each reagent, the normalized result of the difference between the amount taken and the average amount taken is used as the amount deviation parameter, and the normalized result of the difference between the access time and the average access time is used as the access time deviation parameter; the product of the access amount deviation parameter and the access time deviation parameter is used as the access characteristic deviation parameter.

[0007] Furthermore, the method for obtaining the abnormal access process and the normal access process includes: All access processes whose preliminary abnormal coefficient is greater than or equal to a preset coefficient threshold are regarded as abnormal access processes of the corresponding reagents; and all access processes other than the abnormal access processes are regarded as normal access processes.

[0008] Furthermore, the method for obtaining the abnormal utilization coefficient includes: According to the preliminary abnormal coefficient, a mutation access process is screened out from all the abnormal access processes of each reagent, and the access interval sequence is segmented based on the mutation access process to obtain an early segment and a late segment; Normalizing the difference between the mean of the differences between all adjacent taking intervals in the early segment and the mean of the differences between all adjacent taking intervals in the late segment, and using the normalized result as the taking change parameter of the corresponding reagent; The preliminary abnormal coefficient of the mutation access process of each reagent is used as the weight of the corresponding access change parameter, and the weighted result is used as the abnormal access coefficient of the corresponding reagent.

[0009] Furthermore, the method for acquiring the mutation access process includes: Among all the access processes of each reagent, the access process with the largest preliminary abnormality coefficient is taken as the mutation access process.

[0010] Furthermore, the method for obtaining the abnormal state index includes: During the traceability management period of each reagent, the maximum deviation parameter of the amount used during all normal access processes is used as a reference deviation parameter; According to the deviation of the usage deviation parameter in all the abnormal access processes relative to the reference deviation parameter, combined with the usage deviation parameter in all the normal access processes, a state deviation parameter of the corresponding reagent is obtained; The state deviation parameter is used to weight the corresponding abnormal utilization coefficient, the weighted result is normalized, and the normalized result is used as the state abnormality index of the corresponding reagent.

[0011] Furthermore, the method for obtaining the state deviation parameter includes: The normalized result of the difference between the usage deviation parameter in the abnormal access process with the largest preliminary abnormal coefficient and the reference deviation parameter is used as the numerator; the mean of the usage deviation parameters in all normal access processes and the sum of the preset minimum positive parameter are used as the denominator; the fraction ratio is used as the state deviation parameter of the corresponding reagent.

[0012] Furthermore, the method for obtaining the abnormal reagent includes: The reagent whose abnormal state index is greater than or equal to the preset state threshold is regarded as an abnormal reagent.

[0013] Furthermore, the method for obtaining the access interval sequence includes: During the traceability management period of each reagent, the time interval between the retrieval time of each access process and the deposit time of the previous adjacent access process is taken as the access interval, and the access interval is taken as the sequence element, and the access interval sequence is constructed by sorting in chronological order.

[0014] The present invention has the following beneficial effects: The present invention first obtains the amount and duration of each reagent in the intelligent reagent cabinet during each access process during the traceability management period, providing data support for subsequent analysis and evaluation of abnormal access of reagents; and obtains the access interval sequence of each reagent during the traceability management period, preparing for subsequent analysis of the access frequency to assist in evaluating the abnormal state of the reagent; according to the amount and duration of each reagent in each access process, the preliminary abnormal coefficient of each access process of each reagent is obtained, and the preliminary abnormal coefficient preliminarily reflects the abnormal possibility of each reagent in each access process, which is for subsequent preliminary screening of abnormal access processes and normal access processes. The process is prepared by analyzing abnormal access; then during the traceability management period of each reagent, according to the changes in the access interval sequence and the preliminary abnormal coefficients of all abnormal access processes, the abnormal access coefficient of each reagent is obtained. The abnormal access coefficient reflects the abnormal changes in the access of the reagent, and then the quality state change of the reagent can be evaluated from the side; according to the amount of each reagent taken in all abnormal access processes and the amount of each reagent taken in all normal access processes, combined with the corresponding abnormal access coefficient, the state abnormality index reflecting the possibility of the quality state change of each reagent is obtained, thereby helping to accurately screen out abnormal reagents for traceability management. The present invention analyzes the changes in the access of each reagent in different access processes, evaluates the possibility of abnormal access and quality state change of the reagent, and then can accurately screen out abnormal reagents for precise traceability management. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the technical solutions and advantages in the embodiments of the present invention or the prior art, the drawings required for use in the embodiments or the prior art descriptions are briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0016] Figure 1 A flow chart of a reagent storage and access traceability management method applicable to an intelligent reagent cabinet provided by one embodiment of the present invention; Figure 2 A flow chart of a method for obtaining a preliminary anomaly coefficient provided by an embodiment of the present invention; Figure 3 A flow chart of a method for obtaining a status abnormality index provided by an embodiment of the present invention. DETAILED DESCRIPTION

[0017] In order to further explain the technical means and effects adopted by the present invention to achieve the predetermined invention purpose, the following is a detailed description of the reagent access traceability management method suitable for an intelligent reagent cabinet proposed in accordance with the present invention, its specific implementation method, structure, features and effects, in combination with the accompanying drawings and preferred embodiments. In the following description, different "one embodiment" or "another embodiment" does not necessarily refer to the same embodiment. In addition, specific features, structures or characteristics in one or more embodiments may be combined in any suitable form.

[0018] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0019] The following is a detailed description of a specific solution of a reagent storage and access traceability management method applicable to an intelligent reagent cabinet provided by the present invention in conjunction with the accompanying drawings.

[0020] See also Figure 1 , which shows a flow chart of a reagent access traceability management method applicable to a smart reagent cabinet provided by an embodiment of the present invention, specifically comprising: Step S1, obtaining the amount and duration of each reagent in the intelligent reagent cabinet during each access process during the traceability management period, and obtaining the access interval sequence of each reagent during the traceability management period.

[0021] It should be noted that the embodiments of the present invention are aimed at the storage and traceability management of reagents used in repeated experiments within a certain research and experimental stage. That is, the use of the same reagent in different experimental processes should be carried out under standardized operating procedures. If the amount used is determined based on a preset ratio, the amount of the same reagent used in different experimental processes should be similar; the traceability management period is the corresponding research and experimental stage.

[0022] In order to perform traceability management on each reagent in the smart reagent cabinet, an embodiment of the present invention first obtains the amount and duration of each reagent used in each access process during the traceability management period based on the access records of the smart reagent cabinet, so as to provide data support for the subsequent analysis and evaluation of abnormal access of reagents; at the same time, the access intervals between adjacent access processes are obtained to construct an access interval sequence, so as to prepare for the subsequent analysis of the access frequency to assist in the evaluation of the abnormal status of the reagents.

[0023] It should be noted that the acquisition of access records of smart reagent cabinets is a well-known technology. The access records record all access process information of each reagent, including at least the identity information of the access personnel corresponding to each access process, the time of withdrawal, the time of deposit, and the consumption of reagents during the access process, that is, the amount of reagents taken; the time interval between the withdrawal time and the deposit time in each access process is the access time of each access process.

[0024] It should be noted that, in the embodiment of the present invention, the quantity of each reagent in the intelligent reagent cabinet is 1; the access process information of each reagent only includes the access information corresponding to the experimental consumption by the experimenter, and does not include the access information such as the equipment manager of the intelligent reagent cabinet replenishing the inventory or cleaning up abnormal reagents.

[0025] In a preferred embodiment of the present invention, specifically during the traceability management period of each reagent, the time interval between the retrieval time of each access process and the deposit time of the previous adjacent access process is used as the access interval, and the access interval is used as a sequence element, and the access interval sequence is constructed by sorting in chronological order.

[0026] Step S2, according to the amount of each reagent taken and the duration of each access process, obtain the preliminary abnormality coefficient of each access process of each reagent; according to the preliminary abnormality coefficient, obtain all abnormal access processes and all normal access processes of each reagent; during the traceability management period of each reagent, according to the changes in the access interval sequence and the preliminary abnormality coefficients of all abnormal access processes, obtain the abnormal access coefficient of each reagent.

[0027] Considering that the larger the amount of each reagent used in each access process and the longer the access time, it means that the experimenter is more likely to take samples multiple times during the access process, and is more likely to be contaminated and cause abnormal status. In addition, the actual long-term exposure to the experimental environment makes the status more likely to change abnormally. Therefore, the embodiment of the present invention obtains the preliminary abnormality coefficient of each access process of each reagent according to the amount of each reagent used in each access process and the access time. The preliminary abnormality coefficient preliminarily reflects the possibility of abnormality of each reagent in each access process, and prepares for the subsequent preliminary screening of abnormal access processes and normal access processes to analyze abnormal access.

[0028] Preferably, in one embodiment of the present invention, the method for obtaining the preliminary anomaly coefficient includes: See also Figure 2 , which shows a flow chart of a method for obtaining a preliminary abnormal coefficient provided by an embodiment of the present invention, specifically comprising: Step S201, for each reagent, obtaining a withdrawal characteristic deviation parameter according to the deviation of the withdrawal amount in each access process relative to the withdrawal amounts in other access processes, and the deviation of the withdrawal duration in each access process relative to the withdrawal duration in other access processes.

[0029] Considering that the amount and duration of each reagent used should be similar in different access processes, if the amount and duration of a certain access process are more deviated compared with other processes, it means that the access process is more abnormal. Based on this, the two angles of amount and duration can be comprehensively considered to evaluate the deviation parameters of the usage characteristics of each reagent in each access process; the usage characteristic deviation parameters reflect the deviation characteristics of each reagent's access process relative to other access processes, preparing for the subsequent evaluation of the preliminary abnormality coefficient.

[0030] Preferably, in one embodiment of the present invention, the method for obtaining the characteristic deviation parameter includes: In each access process of each reagent, the normalized result of the difference between the amount taken and the average amount taken is used as the amount deviation parameter, and the normalized result of the difference between the access time and the average access time is used as the access time deviation parameter; the product of the access amount deviation parameter and the access time deviation parameter is used as the access characteristic deviation parameter.

[0031] As an example, taking any reagent as an example, the calculation formula of the characteristic deviation parameter is: ; Where i is the serial number of the access process; is the characteristic deviation parameter of the reagent in the ith access process; norm() is the linear normalization function; is the absolute value symbol; is the amount of reagent used in the i-th storage and access process; The average amount of reagent used in all storage and access processes; is the time taken for the i-th access process of the reagent; The average time it takes to access the reagent in all storage and access processes; is the amount deviation parameter of the reagent in the i-th access process; is the time deviation parameter of the i-th access process of the reagent; In the calculation formula of the withdrawal characteristic deviation parameter, the formal difference of the absolute value of the difference is used to evaluate the deviation degree of the withdrawal amount and the deviation degree of the withdrawal time respectively. The larger the absolute value of the difference, the greater the deviation degree; then, by linearly normalizing the absolute value of the difference, the withdrawal amount deviation parameter and the withdrawal time deviation parameter are obtained respectively, and then multiplied and fused to obtain the withdrawal characteristic deviation parameter; when the withdrawal amount deviation parameter and the withdrawal time deviation parameter are both larger, it means that the withdrawal characteristic of the reagent in the corresponding access process is more abnormal.

[0032] Step S202: In each access process of each reagent, the product of the access amount and the access time is used as the access characteristic parameter.

[0033] Considering that in each access process of each reagent, if the amount and the access time are larger and deviate more from the average level, it can be said that the access process is more abnormal; therefore, in the present embodiment of the invention, after obtaining the access characteristic deviation parameter, the amount and the access time in each access process are further fused by multiplication, and the product is used as the access characteristic parameter of the corresponding access process, so as to subsequently evaluate the preliminary abnormality coefficient in combination with the access characteristic deviation parameter.

[0034] Step S203, fusing the characteristic parameters and the characteristic deviation parameters to obtain a preliminary abnormality coefficient.

[0035] As an example, during each access process of each reagent, the product of the access characteristic parameter and the access characteristic deviation parameter is used as the preliminary abnormality coefficient.

[0036] After obtaining the preliminary abnormality coefficient of each access process of each reagent, all abnormal access processes and all normal access processes of each reagent can be further obtained based on the preliminary abnormality coefficient.

[0037] Preferably, in one embodiment of the present invention, considering that the larger the preliminary abnormality coefficient is, the greater the possibility of abnormality of the access process is, the method for obtaining the abnormal access process and the normal access process includes: All access processes whose preliminary abnormal coefficients are greater than or equal to the preset coefficient threshold are regarded as abnormal access processes of the corresponding reagents; and all access processes other than all abnormal access processes are regarded as normal access processes.

[0038] As an example, the preset coefficient threshold is set to 0.7, and the implementer may also set the preset coefficient threshold to any value between 0.7 and 1 according to actual needs.

[0039] Considering that when the quality state of a reagent changes, such as the introduction of impurities or a decrease in concentration due to improper operation, the test results often cannot meet the ideal expectations, the experimenters will conduct multiple experiments to verify the results, thereby increasing the frequency of taking the reagents used; considering that the time interval between adjacent access processes can reflect the frequency of use, the changes in the access interval sequence of each reagent can help to indirectly evaluate whether the quality state of the reagent has changed; Therefore, during the traceability management period of each reagent, the embodiment of the present invention obtains the abnormal access coefficient of each reagent according to the changes in the access interval sequence and the preliminary abnormal coefficients of all abnormal access processes; the abnormal access coefficient evaluates the abnormal situation of reagent access based on the changes in the reagent access interval, and then indirectly evaluates the changes in the quality status of the reagent, thereby helping to accurately screen out abnormal reagents for traceability management.

[0040] Preferably, in one embodiment of the present invention, considering that the larger the preliminary abnormal coefficient is, the more likely it is that the quality state of the reagent will change during the corresponding access process, a turning point of the reagent quality state change can be screened out from all abnormal access processes, and then the difference in the change of the access frequency before and after the turning point is analyzed, and then combined with the preliminary abnormal coefficient of the abnormal access process, the abnormal access coefficient of each reagent is comprehensively evaluated; therefore, the method for obtaining the abnormal access coefficient includes: According to the preliminary abnormal coefficient, the mutant access process is screened out from all abnormal access processes of each reagent, and the access interval sequence is segmented based on the mutant access process to obtain the early segmentation and the late segmentation; Normalize the difference between the mean of the differences between all adjacent use intervals in the early segment and the mean of the differences between all adjacent use intervals in the later segment, and use the normalized result as the use change parameter of the corresponding reagent; The preliminary abnormal coefficient of the mutation access process of each reagent is used as the weight of the corresponding access change parameter, and the weighted result is used as the abnormal access coefficient of the corresponding reagent.

[0041] In a preferred embodiment of the present invention, among all the access processes of each reagent, the access process with the largest initial abnormality coefficient is taken as the mutation access process.

[0042] It should be noted that when the access process with the largest initial abnormality coefficient may be the last access process within the traceability management period, the first abnormal access process within the traceability management period can be regarded as a mutation access process. When the first abnormal access process is still the last access process within the traceability management period, the access process will be directly subject to traceability warning management.

[0043] As an example, after obtaining the mutation access process of each reagent during the traceability management period, the mutation access process is used as the demarcation point, so that the access interval sequence can be segmented accordingly, and the access intervals between all access processes before the mutation access process are corresponding to the sequence elements as the sequence elements in the early segment, thereby obtaining the early segment; the later segment is obtained in the same way; then, taking any reagent as an example, the calculation formula of the abnormal access coefficient is: ; Where S is the abnormal use coefficient of the reagent; is the hyperbolic tangent function, used for normalization; m is the serial number of the interval used in the previous segmentation; M is the total number of intervals used in the previous segmentation; is the mth access interval in the previous segment; is the m+1th interval used in the previous segment; n is the sequence number of the interval used in the later segment; N is the total number of intervals used in the later segment; is the nth access interval in the later segment; is the n+1th access interval in the later segment; is the absolute value symbol; K is the initial abnormal coefficient of the mutation access process.

[0044] In the calculation formula of the abnormal usage coefficient, the change in usage frequency is indirectly reflected through the mean difference between adjacent usage intervals in each segment. The greater the difference between the mean difference between adjacent usage intervals in the previous segment and the mean difference between adjacent usage intervals in the later segment, the greater the difference in usage frequency before and after the mutation access process. The more likely the reagent quality state will change in the mutation access process, the greater the reagent usage change parameter, and the greater the possibility of abnormal usage. The initial abnormal coefficient of the mutation access process is further used as a weight and multiplied by the usage change parameter to perform weighting in order to comprehensively evaluate the abnormal usage coefficient of the reagent.

[0045] Step S3, according to the amount of each reagent taken during all abnormal access processes and the amount of each reagent taken during all normal access processes, combined with the corresponding abnormal access coefficient, obtain the state abnormality index of each reagent; according to the state abnormality index, screen out abnormal reagents from all reagents, and perform access traceability management on the abnormal reagents.

[0046] Considering that changes in the quality status of reagents will not only cause experimenters to increase the frequency of use, but may also increase the amount used each time. For example, if the reagent concentration is suspected to be reduced after multiple experiments, the amount used will be increased for experimental verification. The amount used during abnormal access will usually be higher than the amount used during normal access. Therefore, the embodiment of the present invention will further obtain the state abnormality index of each reagent based on the amount used in all abnormal access processes and the amount used in all normal access processes, and then combine the corresponding abnormal access coefficient. The state abnormality index comprehensively evaluates the possibility of changes in the quality status of the reagent by combining the amount used and the frequency of use, thereby helping to accurately screen out abnormal reagents for traceability management.

[0047] Preferably, in one embodiment of the present invention, the method for obtaining the abnormal state index includes: See also Figure 3 , which shows a flow chart of a method for obtaining a state abnormality index provided by an embodiment of the present invention, specifically comprising: Step S301, during the traceability management period of each reagent, the maximum usage deviation parameter in all normal access processes is used as a reference deviation parameter.

[0048] Considering that the maximum amount deviation parameter in all normal access processes reflects the extreme situation of the reagent's usage deviation during the traceability management period, if the amount deviation parameter in the abnormal access process is greater than the extreme and the larger it is, the higher the possibility of reagent abnormality; based on this, the maximum amount deviation parameter in all normal access processes is used as the reference deviation parameter for reference in subsequent analysis and evaluation.

[0049] Step S302, according to the deviation of the usage deviation parameter in all abnormal access processes relative to the reference deviation parameter, combined with the usage deviation parameter in all normal access processes, the state deviation parameter of the corresponding reagent is obtained.

[0050] Considering that the smaller the deviation parameter of the amount used in all normal access processes is, the greater the reference comparison value for the abnormal access process is, and the more accurate the evaluation result of the abnormal use and quality status change of the reagent is; conversely, the reference comparison significance is lower, and the confidence of the evaluation result is also lower; therefore, the embodiment of the present invention further combines the logical analysis in step S301 to obtain the state deviation parameter of each reagent; the state deviation parameter comprehensively considers the deviation of the amount used in the normal access process and the abnormal access process, reflects the confidence of the abnormal use and quality status change of the reagent, and prepares for the subsequent evaluation of the state abnormality index.

[0051] In a preferred embodiment of the present invention, the method for obtaining the state deviation parameter includes: The normalized result of the difference between the deviation parameter of the amount used in the abnormal access process with the largest preliminary abnormal coefficient and the reference deviation parameter is used as the numerator; the mean of the deviation parameter of the amount used in all normal access processes and the sum of the preset minimum positive parameter are used as the denominator; the fraction ratio is used as the state deviation parameter of the corresponding reagent.

[0052] As an example, taking any reagent as an example, the calculation formula of the state deviation parameter is: ; Where Z is the state deviation parameter of the reagent; norm() is the linear normalization function; The deviation parameter of the amount of reagent used during the abnormal access process with the largest initial abnormal coefficient; is the reference deviation parameter; It is the mean value of the deviation parameter of the amount used in all normal storage and access processes of the reagent; In order to preset the minimum positive parameter, 0.00001 is taken in this example to avoid the denominator being 0 without affecting the calculation result and to ensure that the fraction is meaningful.

[0053] In the calculation formula of the state deviation parameter, the usage deviation parameter in the abnormal access process with the largest preliminary abnormal coefficient has a difference with the reference deviation parameter that is greater than 0. The larger the difference, the more the usage in the abnormal access process deviates from that in the normal access process. The larger the numerator, the higher the credibility of the abnormal usage analysis. The smaller the mean of the usage deviation parameters in all normal access processes and the smaller the denominator, the higher the credibility of the abnormal usage analysis.

[0054] Step S303, weighting the corresponding abnormality coefficient using the state deviation parameter, normalizing the weighted result, and using the normalized result as the state abnormality index of the corresponding reagent.

[0055] As an example, the state deviation parameter of each reagent is multiplied and combined with the abnormal use coefficient, and the product is mapped to the hyperbolic tangent function for normalization. The larger the normalized value, the larger the state abnormality index, the greater the possibility of abnormal use of the reagent and change in quality status, and the more traceability management should be carried out.

[0056] After obtaining the abnormal status index of each reagent, the abnormal reagents can be screened out from all reagents according to the abnormal status index, and then the abnormal reagents can be managed for storage and access traceability.

[0057] Preferably, in one embodiment of the present invention, a reagent whose state abnormality index is greater than or equal to a preset state threshold is regarded as an abnormal reagent; wherein the preset state threshold is set to 0.8, and the implementer may also set the preset state threshold to any value between 0.8 and 1 according to actual needs.

[0058] In one embodiment of the present invention, after screening out all abnormal reagents, the access records of each abnormal reagent during the traceability management period can be traced, further assisting relevant laboratory management personnel in analyzing the causes of abnormal traceability reagents; for example, taking any abnormal reagent as an example, extract the access records corresponding to all abnormal access processes, trace the access personnel and access time, trace the purpose and usage scenario of the reagents, inspect the abnormal reagents, and evaluate the causes of changes in the quality status of the reagents, thereby optimizing the experimental operation standards and improving the reagent management effect.

[0059] In summary, the present invention first obtains the amount and duration of each reagent used in each access process, and obtains the access interval sequence of each reagent; then analyzes and obtains the preliminary abnormal coefficient of each access process of each reagent to obtain all abnormal access processes and all normal access processes; further obtains the abnormal access coefficient of each reagent according to the change of the access interval sequence of each reagent and the preliminary abnormal coefficient of all abnormal access processes; and then combines the amount of each reagent used in all abnormal access processes and the amount of each reagent used in all normal access processes to obtain the state abnormality index of each reagent, thereby screening out abnormal reagents and tracing management. The present invention analyzes the changes in the use of each reagent in different access processes, evaluates the possibility of abnormal use of reagents and changes in quality status, and can accurately screen out abnormal reagents for precise traceability management.

[0060] It should be noted that the sequence of the above embodiments of the present invention is only for description and does not represent the advantages and disadvantages of the embodiments. The processes depicted in the accompanying drawings do not necessarily require the specific order or continuous order shown to achieve the desired results. In some embodiments, multitasking and parallel processing are also possible or may be advantageous.

[0061] The various embodiments in this specification are described in a progressive manner, and the same or similar parts between the various embodiments can be referenced to each other, and each embodiment focuses on the differences from other embodiments.

Claims

1. A reagent storage and access traceability management method applicable to an intelligent reagent cabinet, characterized in that: The method comprises: Obtain the amount and duration of each reagent in the intelligent reagent cabinet during each access process during the traceability management period, and obtain the access interval sequence of each reagent during the traceability management period; According to the amount of each reagent taken and the duration of the use in each access process, obtain the preliminary abnormal coefficient of each access process of each reagent; according to the preliminary abnormal coefficient, obtain all abnormal access processes and all normal access processes of each reagent; during the traceability management period of each reagent, according to the change of the access interval sequence and the preliminary abnormal coefficient of all the abnormal access processes, obtain the abnormal access coefficient of each reagent; According to the amount of each reagent taken during all the abnormal access processes, and the amount of each reagent taken during all the normal access processes, combined with the corresponding abnormal access coefficient, the state abnormality index of each reagent is obtained; according to the state abnormality index, abnormal reagents are screened out from all reagents, and access traceability management is performed on the abnormal reagents.

2. A reagent storage and access traceability management method applicable to an intelligent reagent cabinet according to claim 1, characterized in that: The method for obtaining the preliminary anomaly coefficient includes: Under each reagent, according to the deviation of the amount taken in each access process relative to the amounts taken in other access processes, and the deviation of the access time in each access process relative to the access time in other access processes, obtaining the access characteristic deviation parameter; In each access process of each reagent, the product of the access amount and the access time is used as the access characteristic parameter; The feature parameters and the feature deviation parameters are integrated to obtain a preliminary anomaly coefficient.

3. A reagent storage and access traceability management method applicable to an intelligent reagent cabinet according to claim 2, characterized in that: The method for obtaining the characteristic deviation parameter comprises: In each access process of each reagent, the normalized result of the difference between the amount taken and the average amount taken is used as the amount deviation parameter, and the normalized result of the difference between the access time and the average access time is used as the access time deviation parameter; the product of the access amount deviation parameter and the access time deviation parameter is used as the access characteristic deviation parameter.

4. A reagent storage and access traceability management method applicable to an intelligent reagent cabinet according to claim 1, characterized in that: The method for obtaining the abnormal access process and the normal access process includes: All access processes whose preliminary abnormal coefficient is greater than or equal to a preset coefficient threshold are regarded as abnormal access processes of the corresponding reagents; and all access processes other than the abnormal access processes are regarded as normal access processes.

5. A reagent storage and access traceability management method applicable to an intelligent reagent cabinet according to claim 1, characterized in that: The method for obtaining the abnormal utilization coefficient includes: According to the preliminary abnormal coefficient, a mutation access process is screened out from all the abnormal access processes of each reagent, and the access interval sequence is segmented based on the mutation access process to obtain an early segment and a late segment; Normalizing the difference between the mean of the differences between all adjacent taking intervals in the early segment and the mean of the differences between all adjacent taking intervals in the late segment, and using the normalized result as the taking change parameter of the corresponding reagent; The preliminary abnormal coefficient of the mutation access process of each reagent is used as the weight of the corresponding access change parameter, and the weighted result is used as the abnormal access coefficient of the corresponding reagent.

6. A reagent storage and access traceability management method applicable to an intelligent reagent cabinet according to claim 5, characterized in that: The method for obtaining the mutation access process includes: Among all the access processes of each reagent, the access process with the largest preliminary abnormal coefficient is taken as the mutation access process.

7. A reagent storage and access traceability management method applicable to an intelligent reagent cabinet according to claim 3, characterized in that: The method for obtaining the abnormal state index includes: During the traceability management period of each reagent, the maximum deviation parameter of the amount used during all normal access processes is used as a reference deviation parameter; According to the deviation of the usage deviation parameter in all the abnormal access processes relative to the reference deviation parameter, combined with the usage deviation parameter in all the normal access processes, a state deviation parameter of the corresponding reagent is obtained; The state deviation parameter is used to weight the corresponding abnormal utilization coefficient, the weighted result is normalized, and the normalized result is used as the state abnormality index of the corresponding reagent.

8. A reagent storage and access traceability management method applicable to an intelligent reagent cabinet according to claim 7, characterized in that: The method for obtaining the state deviation parameter includes: The normalized result of the difference between the usage deviation parameter in the abnormal access process with the largest preliminary abnormal coefficient and the reference deviation parameter is used as the numerator; the mean of the usage deviation parameters in all normal access processes and the sum of the preset minimum positive parameter are used as the denominator; the fraction ratio is used as the state deviation parameter of the corresponding reagent.

9. A reagent storage and access traceability management method applicable to an intelligent reagent cabinet according to claim 1, characterized in that: The method for obtaining the abnormal reagent comprises: The reagent whose abnormal state index is greater than or equal to the preset state threshold is regarded as an abnormal reagent.

10. A reagent storage and access traceability management method applicable to an intelligent reagent cabinet according to claim 1, characterized in that: The method for obtaining the access interval sequence comprises: During the traceability management period of each reagent, the time interval between the retrieval time of each access process and the deposit time of the previous adjacent access process is taken as the access interval, and the access interval is taken as the sequence element, and the access interval sequence is constructed by sorting in chronological order.

Images